Yale University

R. Douglas Bruce, M.D., M.A., M.S.

  • Associate Chief of Clinical Affairs, Boston Medical Center
  • Associate Professor of Medicine, Boston University School of Medicine


From academics to public/community health, Dr. Bruce has worked to develop and implement research and public health interventions both locally and internationally. Dr. Bruce is a global expert in substance use disorders among people with HIV/Hepatitis C and serves as the substance use team lead for the Department of Health and Human Services Antiretroviral Guideline committee. From drug-drug interactions work to ascertain the impact of HIV and HCV therapeutics on methadone/buprenorphine to operations research to improve HIV/HCV and tuberculosis care, Dr. Bruce has translated research into the clinical environment to improve outcomes for people who use drugs.

A significant portion of Dr. Bruce’s work has focused on the impact of addiction on HIV globally. In Tanzania, for example, Dr. Bruce helped establish a treatment for opioid use disorders to combat the growing HIV incidence rate among people who inject drugs (42% of people injecting had HIV). In late 2009, he worked with local leaders and the CDC to create national treatment standards for Tanzania and co-authored the first full draft of those guidelines for the country. In 2010, he worked to establish, train, and mentor clinical staff in preparation for starting the first public methadone program in continental sub-Sahara Africa, which started dosing in February 2011. The program has grown from one clinic in Dar es Salaam to a national program across Tanzania with thousands in treatment. A hallmark of the clinics established in Dar es Salaam was the integration of addiction, HIV and tuberculosis. In addition to the work in Tanzania, Dr. Bruce has provided technical assistance to the United Nations, USAID, CDC, and non-governmental organizations to address HIV and substance use epidemics in Central Asia, Ukraine, Malaysia, and Africa.

In the last several years, Dr. Bruce returned to New Haven, CT to help transform the local community and improve the clinical care there. He transitioned out of his research role at Yale and took the Chief of Medicine position at Cornell Scott-Hill Health Center (CSHHC). This health center was the first FQHC in Connecticut and is one of the largest, providing care to south-central Connecticut to over 34,000 patients.